ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database

W. S. Cherikh1, T. Kou2, J. Foutz1, A. Gomez-Caminero2

1United Network for Organ Sharing (UNOS), Richmond, VA, 2Bristol-Myers Squibb, Princeton, NJ

Meeting: 2020 American Transplant Congress

Abstract number: 500

Keywords: Epstein-Barr virus (EBV), Immunosuppression, Kidney transplantation, Post-transplant lymphoproliferative disorder (PTLD)

Session Information

Session Name: PTLD/Malignancies

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:39pm-3:51pm

Location: Virtual

*Purpose: Belatacept, a selective T-cell costimulation blocker, was approved in 2011 for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients. PTLD is a recognized complication of kidney transplantation and is a safety concern with belatacept use. Here, we report results from two US-based observational studies that utilized data from the OPTN database to examine patterns of belatacept use and the incidence of PTLD in kidney transplant recipients in clinical practice between June 15, 2011 and June 14, 2016.

*Methods: Adult recipients of kidney-alone transplants who received belatacept or calcineurin inhibitor (CNI)-based regimens at transplant were included. Primary objectives were to assess the prevalence of belatacept use, to examine user characteristics including EBV serostatus, and to estimate PTLD incidence rates in adult EBV-seropositive recipients treated with belatacept or CNI at transplant.

*Results: Overall, 1737 kidney transplant recipients received belatacept at transplant, of whom 1719 had known EBV serostatus and 1631 (93.9% of the overall patient population and 94.9% of patients with known serostatus) were EBV seropositive. A total of 59,992 EBV-seropositive kidney-only transplant recipients received CNI at transplant. In the EBV-seropositive belatacept-treated and CNI-treated groups, respectively, 62.4% and 60.5% were male, 45.1% and 46.6% were aged 40-59 years at transplant, 50.2% and 56.8% received a standard criteria donor kidney, 59.5% and 18.7% received basiliximab for induction, and 22.9% and 50.8% received thymoglobulin for induction. Among EBV-seropositive recipients, 9 PTLD events (2 with known central nervous system [CNS] involvement) were reported in the belatacept group and 225 PTLD events (9 with known CNS involvement) were reported in the CNI group (PTLD incidences are shown in Table 1). PTLD was the cause of death in 4 of 9 belatacept-treated and 81 of 225 CNI-treated patients who developed PTLD. Kaplan-Meier analysis did not show a significant difference in the rates of PTLD between the two groups.

*Conclusions: Since the FDA approval of belatacept in 2011, the majority of adult kidney-only transplant recipients treated with belatacept were EBV seropositive. The risk of PTLD in belatacept-treated EBV-seropositive patients remained low in routine clinical practice and was consistent with observations from previous clinical studies.

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Cherikh WS, Kou T, Foutz J, Gomez-Caminero A. Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/patterns-of-belatacept-use-and-risk-of-post-transplant-lymphoproliferative-disorder-ptld-in-us-kidney-transplant-recipients-analysis-of-organ-procurement-and-transplantation-network-optn-databas/. Accessed June 6, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences